Antibody-directed enzyme prodrug therapy (ADEPT) for cancer

被引:59
作者
Bagshawe, KD
Sharma, SK
Begent, RHJ
机构
[1] UCL, Royal Free & Univ Coll, Sch Med, Dept Oncol, London NW3 2PF, England
[2] Univ London Imperial Coll Sci & Technol, Dept Med Oncol, London W6 8RF, England
关键词
ADEPT; enzyme; fusion protein; prodrug;
D O I
10.1517/14712598.4.11.1777
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Antibody-directed enzyme prodrug therapy (ADEPT) aims to restrict the cytotoxic action to tumour sites. The obstacles to achieve this were recognised at the outset, but time and experience have given these better definition. The development of fusion proteins has provided the means of making consistent antibody-enzyme constructs on an adequate scale, and glycosylation has provided the means to control the clearance of enzyme from non-tumour sites. Human enzymes have yet to be tested in a clinical setting, and there are pointers indicating that the immunological response to foreign enzymes can be overcome. The relatively small number of purpose-designed prodrugs tested so far leaves this an area ripe for further development. The ongoing iterative process between preclinical and clinical studies is critical to achieving the objective.
引用
收藏
页码:1777 / 1789
页数:13
相关论文
共 108 条
  • [21] BOSSLET K, 1994, CANCER RES, V54, P2151
  • [22] Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates
    Caliceti, P
    Veronese, FM
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2003, 55 (10) : 1261 - 1277
  • [23] CHABNER BA, 1972, CANCER RES, V32, P2114
  • [24] Poly(ethylene glycol) modification of beta-glucuronidase-antibody conjugates for solid-tumor therapy by targeted activation of glucuronide prodrugs
    Cheng, TL
    Chen, BM
    Chan, LY
    Wu, PY
    Chern, JW
    Roffler, SR
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 1997, 44 (06) : 305 - 315
  • [25] Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgM
    Cheng, TL
    Wu, PY
    Wu, MF
    Chern, JW
    Roffler, SR
    [J]. BIOCONJUGATE CHEMISTRY, 1999, 10 (03) : 520 - 528
  • [26] Bystander killing of tumour cells by antibody-targeted enzymatic activation of a glucuronide prodrug
    Cheng, TL
    Wei, SL
    Chen, BM
    Chern, JW
    Wu, MF
    Liu, PW
    Roffler, SR
    [J]. BRITISH JOURNAL OF CANCER, 1999, 79 (9-10) : 1378 - 1385
  • [27] PHAGE LIBRARIES FOR GENERATION OF CLINICALLY USEFUL ANTIBODIES
    CHESTER, KA
    BEGENT, RHJ
    ROBSON, L
    KEEP, P
    PEDLEY, RB
    BODEN, JA
    BOXER, G
    GREEN, A
    WINTER, G
    COCHET, O
    HAWKINS, RE
    [J]. LANCET, 1994, 343 (8895) : 455 - 456
  • [28] THE 3 MOUSE MULTIDRUG RESISTANCE (MDR) GENES ARE EXPRESSED IN A TISSUE-SPECIFIC MANNER IN NORMAL MOUSE-TISSUES
    CROOP, JM
    RAYMOND, M
    HABER, D
    DEVAULT, A
    ARCECI, RJ
    GROS, P
    HOUSMAN, DE
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1989, 9 (03) : 1346 - 1350
  • [29] A33scFv-cytosine deaminase: a recombinant protein construct for antibody-directed enzyme-prodrug therapy
    Deckert, PM
    Renner, C
    Cohen, LS
    Jungbluth, A
    Ritter, G
    Bertino, JR
    Old, LJ
    Welt, S
    [J]. BRITISH JOURNAL OF CANCER, 2003, 88 (06) : 937 - 939
  • [30] DRUG POLYMER CONJUGATES - POTENTIAL FOR IMPROVED CHEMOTHERAPY
    DUNCAN, R
    [J]. ANTI-CANCER DRUGS, 1992, 3 (03) : 175 - 210